From research to real-world solutions, Janssen has a legacy of developing treatments for mental illnesses. For more than 50 years, our unwavering commitment to mental health has led to innovative products to treat schizophrenia, schizoaffective disorder and bipolar disorder, and we are working to bring forward new products for Alzheimer’s disease and severe mood disorders.
While we are a business that focuses on mental health solutions, we care deeply about the overall well-being of our patients and their families, including their access to education regarding the treatment of mental illness. Janssen is dedicated to shifting perceptions and eliminating the stigma of mental health issues around the world by providing access, education, support and treatment to individuals seeking help, as well as to the general public.
We are proud of how we connect our community work in mental health with our sustainability goals, which encompass all of the ways which we impact the world – advancing human health and well-being, safeguarding the planet, keeping our business strong and conducting business responsibly – now and for the long term.
To learn more about our neuroscience areas of focus and interest, as well as our capabilities, visit the Neuroscience section.
We have worked for many years in the Philippines to accelerate progress in the fight against mental illness. We coproduced an award-winning, full-length feature film, Mga Anino ng Kahapon (Shadows of the Past), in 2013 about a Filipino family struggling to overcome the challenges of schizophrenia. We also partnered with the government and leading medical institutions to launch the country’s first mental health information system.
Our commitment to supporting programs that strengthen health systems and reduce the societal impact and stigma attached to living with mental illness help us to deliver on our vision for mental health around the world. Along with the communities we serve, we embrace a future for people living with mental illnesses that is stigma-free and includes access to optimal care.
It is estimated that there were 35.6 million people with dementia, including Alzheimer’s disease, worldwide in 2010. This number is projected to nearly double every 20 years, increasing to 65.7 million in 2030 and 115.4 million in 2050.
As part of its commitment to education and awareness building, the Janssen Europe, Middle East, and Africa (EMEA) team launched Dementia.com in September 2013 to provide dementia patients, caregivers and family members with resources on the causes, symptoms and treatments for dementia. We also offer guides on preventative care and how to differentiate age-related memory loss from the more severe impact of neurodegenerative diseases such as Alzheimer’s.